



## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	<b>Component Charting Name</b>	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
0010020	ABSC-R	Antibody Screen RBC with Reflex to Identification											x								
0013003	IRL-AB PKG	Antibody ID Package (IRL)																		х	
0013005	IRL-ABID	Antibody ID RBC Prenatal- Reflex to Titer																		x	
0020763	PCT	Procalcitonin			Х	х			х												
0040248	KRAS	KRAS Mutation Detection																			х
0049000	LAP	Leukocyte Alkaline Phosphatase (Test on Delay as of 7/21/2023)																			х
0051750	BRAF RFLX	BRAF Codon 600 Mutation Detection with Reflex to MLH1 Promoter Methylation																		x	
0055567	T CELL-F	T-Cell Clonality Screening by PCR			х																
0080260	PBGQT	Porphobilinogen (PBG), Urine					х		x	x		x									
0090120	ЕТОН	Ethanol, Serum or Plasma - Medical														х					
0092099	CD20	B-Cell CD20 Expression (Change effective as of 03/20/24: Refer to 3016431)																		x	
2002181	PORUFPBG U	Porphyrins and Porphobilinogen (PBG), Urine					х		x	x		х									





## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	<b>Component Charting Name</b>	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
2002296	CHR ST	Chromosome Analysis, Solid Tumor			x																
2002300	CHR ONC	Chromosome Analysis, Lymph Node			х			х													
2002327	MSI REFLEX	Mismatch Repair by Immunohistochemistry with Reflex to BRAF Codon 600 Mutation and MLH1 Promoter Methylation		x			x	x					х								
2002440	EGFR PCR	EGFR Mutation Detection by Pyrosequencing																			x
2002498	BRAF PCR	BRAF Codon 600 Mutation Detection by Pyrosequencing																		х	
2003036	AQP4	Aquaporin-4 Receptor Antibody (Change effective as of 05/20/24: Refer to 2013320)																		x	
2003040	PM/SCL	PM/Scl-100 Antibody, IgG by Immunoblot			х																
2003123	NRAS	NRAS Mutation Detection by Pyrosequencing																			X
2005685	JPN M	Japanese Encephalitis Virus Antibody, IgM by ELISA (Change effective as of 05/20/24: Refer to 2005689)																		х	



## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	<b>Component Charting Name</b>	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
2005687	JPN G	Japanese Encephalitis Virus Antibody, IgG by ELISA (Change effective as of 05/20/24: Refer to 2005689)																		x	
2006193	BCELL SCRN	B-Cell Clonality Screening (IgH and IgK) by PCR			х																
2006444	IDH1-2	IDH1 and IDH2 Mutation Analysis, exon 4																			х
2009318	MYD88	MYD88 L265P Mutation Detection by PCR, Quantitative			x																
2010136	CDCO ETOH	Alcohol, Urine, Quantitative														х					
2011476	UPBGQTRA ND	Porphobilinogen (PBG), Random Urine(Change effective as of 05/20/24: Refer to 0080260 in the May Hotline)																		х	
2012052	HHA SEQ	Hereditary Hemolytic Anemia Panel Sequencing			х																
2012173	U3 FIB	Fibrillarin (U3 RNP) Antibody, IgG			х																
2013284	22C3 IP	PD-L1 22C3 IHC with Tumor Proportion Score (TPS) Interpretation, pembrolizumab (KEYTRUDA) and cemiplimab- rwlc (LIBTAYO)																		x	





## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	<b>Component Charting Name</b>	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
2013327	AQP4 R	Aquaporin-4 Receptor Antibody by ELISA with Reflex to Aquaporin-4 Receptor Antibody, IgG by IFA (Change effective as of 05/20/24: Refer to 2013320)																		x	
3000082	ANA IFA AB	Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA			х	х															
3000197	22C3 GAST	PD-L1 22C3 IHC with Combined Positive Score (CPS) Interpretation, pembrolizumab (KEYTRUDA)																		x	
3000399	QFT-4	QuantiFERON-TB Gold Plus, 4-Tube																		x	
3000400	QFT-PLUS	QuantiFERON-TB Gold Plus, 1-Tube																		x	
3000479	SSC PANEL	Criteria Systemic Sclerosis Panel			х																
3001161	FLT3-PCR	FLT3 ITD and TKD Mutation Detection			х																
3002063	FISHMMP	Multiple Myeloma Panel by FISH			х			x													
3002105	U-PEP	Monoclonal Protein Study, 24 hour, Urine					х					х									



## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	Component Charting Name	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
3002134	IDH1 RFLX	IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4		x				x					x								
3002135	OLIGO PAN	1p19q Deletion by FISH and IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4		x				x					x								
3002479	LIVER PAN	Autoimmune Liver Disease Reflexive Panel			х	х															
3003086	FA PRO RBC	Fatty Acids Profile, Essential in Red Blood Cells			х																
3004267	IDH12FFPE	IDH1 and IDH2 Mutation Analysis Exon 4, Formalin- Fixed, Paraffin-Embedded (FFPE) Tissue																		х	
3004277	MSIPCR	Microsatellite Instability (MSI) HNPCC/Lynch Syndrome by PCR			х																
3004308	MLH1 PCR	MLH1 Promoter Methylation			х																
3005956	MGMT METH	MGMT Promoter Methylation Detection by ddPCR			x																





## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	<b>Component Charting Name</b>	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
3006049	AE CSF	Autoimmune Encephalitis Reflex Panel, CSF (Change effective as of 05/20/24: Refer to 3006202, 3006211)																		x	
3006050	ENCEPHEXT 2	Autoimmune Encephalitis Extended Panel, Serum (Change effective as of 05/20/24: Refer to 3006201, 3006210)																		x	
3006285	ADIPO SP	Adiponectin Quantitative, Serum/Plasma (Change effective as of 05/20/24: Refer to 3017195 in the May Hotline)																		x	
3016431	CD20 QUANT	B-Cell CD20 Expression by Flow Cytometry, Quantitative	х																		
3016444	РНОЅРНО Т	Phospho-Tau/Total-Tau/A Beta42, CSF (Change effective as of 05/20/24: Refer to 3017653 in the May Hotline)																		x	
3017050	RAPID AML	Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel	x																		
3017195	ADIP SP	Adiponectin, Quantitative Serum/Plasma	х																		



## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	Component Charting Name	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
3017203	BRAF NGS	BRAF Mutation Detection (Available May 3, 2024)	х																		
3017204	BRAF REFL	BRAF Mutation Detection with Reflex to MLH1 Promoter Methylation (Available May 3, 2024)	x																		
3017209	CRC MUT	Colorectal Cancer Mutation Panel (Available May 3, 2024)	х																		
3017222	IDH1-IDH2	IDH1 and IDH2 Mutation Detection (Available May 3, 2024)	х																		
3017230	LUNG MUT	Lung Cancer Mutation Panel (Available May 3, 2024)	х																		
3017233	MEL MUT	Melanoma Mutation Panel (Available May 3, 2024)	х																		
3017372	TPMTGENO	TPMT Genotyping	х																		
3017373	NUDT15GEN O	NUDT15 Genotyping	х																		
3017399	TPSAB1	TPSAB1 Copy Number Analysis by ddPCR (Available May 3, 2024)	x																		
3017440	MA2/TA CSF	Ma2/Ta Antibody, IgG by Immunoblot, CSF	х																		
3017441	MA2/TA SER	Ma2/Ta Antibody, IgG by Immunoblot, Serum	х																		
3017549	HLA B51	HLA-B51 Genotyping, Behcet Disease (Available May 3, 2024)	x																		
3017554	QFT PLUS	QuantiFERON TB-Gold Plus, 1-Tube	x																		
3017562	QFT 4	QuantiFERON TB-Gold Plus, 4-Tube	х																		





## Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	Component Charting Name	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
3017565	TRI A 19	Allergen, Food, Wheat Component rTri a 19 Omega 5-Gliadin, IgE	х																		
3017569	WHEAT R	Allergen, Food, Wheat and nGliadin With Reflex to Components, IgE	x																		
3017610	IRL AB PKG	RBC Antibody ID Package (IRL)	х																		
3017611	IRL ABID	RBC Antibody ID Prenatal - Reflex to Titer	х																		
3017615	PDL1 22C3	PD-L1 22C3 by IHC	х																		
3017651	VIT C IV	Vitamin C, Plasma (High-Dose Therapy) (Available May 3, 2024)	x																		
3017653	ADMRKS CSF	Alzheimer's Disease Markers, CSF	x																		



## Antibody Screen RBC with Reflex to Identification

0010020, ABSC-R

Specimen Requirements:

**Patient Preparation:** 

Collect: Lavender (K2EDTA) or Pink (K2EDTA).

Specimen Preparation: Do not freeze. Transport 7 mL whole blood. (Min: 3 mL)

Effective Date: May 20, 2024

Transport Temperature: Refrigerated.

Unacceptable Conditions: Plasma Separator Tubes.

Remarks:

Stability: Ambient: Unacceptable; Refrigerated: 1 week; Frozen:

Unacceptable

Methodology: Solid Phase Technology

Performed: Mon-Fri

Reported: 1-3 days

Note: If Antibody Screen is positive, Antibody Identification will be

added. Additional charges apply.

CPT Codes: 86850; additional CPT codes may apply

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

Test Number	Components	Reference Interval
	Antibody Screen Automated	Negative

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.



Procalcitonin 0020763, PCT

Specimen Requirements:

Patient Preparation: The same specimen type (serum, plasma) should be used

throughout the patient's clinical course.

Collect: Plasma <u>separator tube</u> (PST) or <u>serum</u>

separator tube Serum Separator Tube (SST).

Specimen Preparation: For Allow serum specimens, ensure that complete to sit for 15-

20 minutes for proper clot formation has taken place prior to centrifugation. If and to ensure the specimen is centrifuged before complete clot formation, the presence of fibrin

Effective Date: May 20, 2024

may cause erroneous results. The use of plasma is

recommended for rapid turnaround of results. For accurate results, in the serum and plasma specimens should be free of fibrin, red blood cells, and other particulate matter. which can interfere with this assay. Separate from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP standard transport tube. Standard Transport Tube. (Min: 0.3)

mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Specimens collected in citrate anticoagulant.

Specimens that are heat-inactivated, pooled, grossly

hemolyzed, contain obvious microbial contamination or fungal

growth should not be used.

Remarks:

Stability: After separation from cells: Ambient: 24 hours; Refrigerated: 5

days; Frozen: 15 days

Methodology: Quantitative Chemiluminescent Immunoassay (CLIA)

Performed: Sun-Sat

Reported: Within 24 hours

Note: Procalcitonin levels below 0.50 ng/mL do not exclude an

infection, because localized infections (without systemic signs)

may also be associated with such low levels.

CPT Codes: 84145



New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

<u>Procalcitonin >A correction has been applied to optimize cutoffs established for the BRAHMS PCT sensitive KRYPTOR assay.</u>

Effective Date: May 20, 2024

Procalcitonin > 2.00 ng/mL: Procalcitonin levels above 2.00 ng/mL on the first day of ICU admission represent a high risk for progression to severe sepsis and/or septic shock.

Procalcitonin < 0.50 ng/mL: Procalcitonin levels below 0.50 ng/mL on the first day of ICU admission represent a low risk for progression to severe sepsis and/or septic shock.

If the procalcitonin measurement is performed shortly after the systemic infection process has started (usually less than 6 hours), these values may still be low. As various noninfectious noninfectious noninfectious conditions are known to induce procalcitonin as well, procalcitonin levels between 0.50 ng/mL and 2.00 ng/mL should be reviewed carefully to take into account the specific clinical background and condition(s) of the individual patient.

Reference Interval:

Less than 0.07 ng/mL



T-Cell Clonality Screening by PCR

0055567, T CELL-F

**Specimen Requirements:** 

Patient Preparation:

Collect: Whole blood or bone marrow in lavender (EDTA), tissue,

formalin-fixed tissue.

Specimen Preparation: Whole Blood: Do not freeze. Transport 5 mL. (Min: 1 mL) Bone

Marrow: Do not freeze. Transport 3 mL. (Min: 1 mL) Fresh Tissue: Freeze immediately. Transport 100 mg or 0.5-2.0 cm3 tissue FFPE Tumor Tissue: Formalin fixed (10 percent neutral buffered formalin) and paraffin embedded tissue. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or four 10-micron shavings in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect(TM) or contact ARUP Client

Effective Date: May 20, 2024

Services at 800-522-2787.

Transport Temperature: Whole Blood, Bone Marrow: Refrigerated. Fresh Tissue: Frozen

on dry ice. FFPE Tumor Tissue: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during

summer months.

Unacceptable Conditions: Plasma, serum. Specimens collected in anticoagulants other

than EDTA. Clotted or grossly hemolyzed specimens. Tissue: FFPE specimens fixed in any fixative other than 10 percent neutral buffered formalin. Bone Decalcified specimens

submitted in non-EDTA decalcifier.

Remarks: If multiple specimens (blocks or slides) are sent to ARUP, they

must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until

clarification is provided.

Stability: Whole Blood or Bone Marrow: Refrigerated: 7 days; Frozen:

Unacceptable Fresh Tissue: Ambient: Unacceptable; Refrigerated: 2 hours; Frozen: 1 year FFPE Tumor Tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen:

Unacceptable



Methodology: Capillary Electrophoresis/Polymerase Chain Reaction (PCR)

Performed: Varies

Reported: 5-9 days

Note: CPT Codes: 81342

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data: Refer to report.

Reference Interval:



Porphobilinogen (PBG), Urine

0080260, PBGQT

Specimen Requirements:

Patient Preparation:

Collect: Random or 24-hour urine. Refrigerate 24-hour specimens

during collection.

Specimen Preparation: Protect from light. Transfer 28 mL aliquot from a random or

well-mixed 24-hour collection to ARUP <u>amber transport</u> <u>tubes. Amber Transport Tubes.</u> (Min: <u>1</u>3.5 mL) Record total volume and collection time interval on transport tube and test

Effective Date: May 20, 2024

request form.

Transport Temperature: Frozen.

Unacceptable Conditions: Body fluids other than urine.

Remarks:

Stability: Ambient: Unacceptable; Refrigerated: <a href="1">1 week4 days</a>; Frozen: 1

month

Methodology: Quantitative Ion Exchange

Chromatography/Spectrophotometry

Performed: <u>Sun-Sat Mon-Fri</u>

Reported: 1-<u>5</u>4 days

Note: Appropriate test to rule out acute intermittent porphyria (AIP)

and other acute attack types of porphyrias associated with

neurologic and/or psychiatric symptoms.

CPT Codes: 84110

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Porphobilinogen (PBG), Urine

Results for random urine specimens are normalized to creatinine (CRT) concentration and reported as a ratio of amounts (millimoles of PBG/mole of creatinine).

Porphobilinogen (PBG) in a random urine specimen is used to evaluate an attack of acute porphyria. Slight increases in urinary PBG are associated with acute porphyrias other than acute



intermittent porphyria (AIP) and may indicate a resolving or treated acute porphyria.

Urinary PBG in excess of two times the upper reference limit is consistent with acute porphyria.

Effective Date: May 20, 2024

Per 24h calculations are provided to aid interpretation for collections with a duration of 24 hours and an average daily urine volume. For specimens with notable deviations in collection time or volume, ratios of analytes to a corresponding urine creatinine concentration may assist in result interpretation.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

#### Reference Interval:

Test Number	Components	Reference Int	erval	
	Creatinine, Urine - per 24h			
		Age	Male (mg/d)	Female (mg/d)
		3-8 years	140-700	140-700
		9-12 years	300-1300	300-1300
		13-17 years	500-2300	400-1600
		18-50 years	1000-2500	700-1600
		51-80 years	800-2100	500-1400
		81 years and older	600-2000	400-1300
	Porphobilinogen, Urine - per 24h	0. <u>4 - 1.5</u> 0-11.	0 μmol/d	
	Porphobilinogen <u>. (PBG)</u> , Urine - <u>ratio to</u> <u>CRTper volume</u>	0.0 <u>- 0.2 mmc</u>	l/mol CRT-8.8	μmol/L

HOTLINE NOTE: There is a component change associated with this test. One or more components have been added or removed. Refer to the Hotline Test Mix for interface build information.



Ethanol, Serum or Plasma - Medical 0090120, ETOH

Specimen Requirements:

Patient Preparation: For medical purposes only. Timing of specimen collection:

Dependent on time of exposure, test upon presentation to

Effective Date: May 20, 2024

hospital.

Collect: Plain Red. Also acceptable: Lavender (EDTA), Pink (K2EDTA), or

Gray (Potassium Oxalate/Sodium Fluoride).

Specimen Preparation: Separate from cells ASAP or within 2 hours of collection.

Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.3 mL) Cap tube tightly to minimize alcohol loss. When drawing a blood specimen for alcohol testing, use a

nonalcohol-based cleanser at the venipuncture site.

Transport Temperature: Refrigerated.

Unacceptable Conditions: Whole blood. Plasma Separator Tubes (PST), Serum Separator

Tubes (SST).

Remarks:

Stability: After separation from cells: Ambient: 1 week; Refrigerated: 2

week; Frozen: 1 months

Methodology: Quantitative Gas Chromatography

Performed: Sun-Sat

Reported: 1-3 days

Note:

CPT Codes: 80320 (Alt code: G0480)

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Toxic concentrations may cause inebriation, CNS depression, respiratory depression, mental and motor impairment and liver damage. In children, ethanol ingestion may cause hypoglycemia.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:



## Effective February 19, 2013

Normal Range	Not established. Limit of detection varies based on instrumentation.
Therapeutic Range	(Therapy for methanol toxicity): 100-200 mg/dL
Toxic Level	Greater than 250 mg/dL

HOTLINE NOTE: There is a numeric map change associated with this test. Refer to the Hotline Test Mix for interface build information.



Porphyrins and Porphobilinogen (PBG), Urine 2002181, PORUFPBGU

Specimen Requirements:

**Patient Preparation:** 

Collect: 24-hour or random urine. Refrigerate 24-hour specimens during

collection.

Specimen Preparation: Protect from light. Transfer 8 mL aliquot to an ARUP amber

> transport tube Amber Transport Tube. (Min: 4 mL) Record total volume and collection time interval on transport tube and test

Effective Date: May 20, 2024

request form.

**Transport Temperature:** Frozen.

**Unacceptable Conditions:** Body fluids other than urine.

Remarks:

Ambient: Unacceptable; Refrigerated: 4 days; Frozen: 1 month Stability:

Methodology: **Quantitative** High Performance Liquid Chromatography

> (HPLC)/lon Exchange Chromatography/Quantitative Spectrophotometry/Quantitative High Performance Liquid

Chromatography-Tandem Mass Spectrometry

Performed: Sun-Sat Mon-Fri

Reported: 2-5 days

Note: Urine porphyrins are useful for the evaluation of cutaneous

> photosensitivity to exclude porphyria cutanea tarda (PCT). Urine porphobilinogen (PBG) is useful for the evaluation of neurologic and/or psychiatric symptoms to exclude acute

porphyrias such as acute intermittent porphyria (AIP).

**CPT Codes:** 84120; 84110

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Results are normalized to creatinine concentration and reported as a ratio of amounts (micromoles of porphyrin/moles of creatinine).

Porphobilinogen (PBG), Urine



Results for random urine specimens are normalized to creatinine (CRT) concentration and reported as a ratio of amounts (millimoles of PBG/mole of creatinine).

Effective Date: May 20, 2024

Porphobilinogen (PBG) in a random urine specimen is used to evaluate an attack of acute porphyria. Slight increases in urinary PBG are associated with acute porphyrias other than acute intermittent porphyria (AIP) and may indicate a resolving or treated acute porphyria.

<u>Urinary PBG in excess of two times the upper reference limit is consistent with acute porphyria.</u>

Per 24h calculations are provided to aid interpretation for collections with a duration of 24 hours and an average daily urine volume. For specimens with notable deviations in collection time or volume, ratios of analytes to a corresponding urine creatinine concentration may assist in result interpretation.

Per 24h calculations are provided to aid interpretation for collections with a duration of 24 hours and an average daily urine volume. For specimens with notable deviations in collection time or volume, ratios of analytes to a corresponding urine creatinine concentration may assist in result interpretation.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

#### Reference Interval:

Test Number	Components	Reference Inte	erval					
	Creatinine, Urine - per 24h							
		Age	Male (mg/d)	Female (mg/d)				
		3-8 years	140-700	140-700				
		9-12 years	300-1300	300-1300				
		13-17 years	500-2300	400-1600				
		18-50 years	1000-2500	700-1600				
		51-80 years 800-2100 500-1400						
		81 years and older	600-2000	400-1300				
	Porphobilinogen <u>. (PBG),</u> Urine - <u>ratio to</u> <u>CRTper volume</u>	0.0 <u>- 0.2 mmo</u>	I/mol CRT-8.8	μmol/L				
	Uroporphyrin - ratio to CRT	0-4 μmol/mol	CRT					
	Heptacarboxylate - ratio to CRT	0-2 μmol/mol CRT						
	Porphobilinogen (PBG), Urine -per 24h	0. <u>4 - 1.5</u> 0-11.0 μmol/d						
	Coproporphyrin I - ratio to CRT	0-6 μmol/mol CRT						
	Coproporphyrin III - ratio to CRT	0-14 μmol/mo	l CRT					

HOTLINE NOTE: There is a component change associated with this test. One or more components have been added or removed. Refer to the Hotline Test Mix for interface build information.



Chromosome Analysis, Solid Tumor

2002296, CHR ST

Specimen Requirements:

**Patient Preparation:** 

Collect: Thaw media prior to tissue inoculation.

<u>Collect a 10mm solid tumor tissue biopsy (minimum of 5mm)</u> <u>in a sterile, screw-top container filled with tissue culture</u>

Effective Date: May 20, 2024

transport medium.

Specimen Preparation: DO NOT FREEZE. Do not place in formalin. Transport a 10 mm

solid tumor tissue biopsy in a sterile, screw-top container filled

with tissue culture transport medium. (Min: 5 mm).)

Transport Temperature: Room temperature.

Unacceptable Conditions: Frozen specimens. Specimens preserved in formalin.

Remarks:

Stability: Ambient: 48 hours; Refrigerated: 48 hours; Frozen:

Unacceptable

Methodology: Giemsa Band

Performed: Sun-Sat

Reported: 14-28 days

Note: These studies involve culturing of living cells; therefore,

subject to multiple variables. A processing fee will be charged if this procedure is canceled at the client's request after the test has been set up or if the specimen integrity is inadequate to allow culture growth. Place solid tumor biopsy in a sterile, screw-top container filled with tissue culture transport medium (ARUP Supply #32788). Available online through eSupply using ARUP ConnectorConnect(TM) or contact ARUP Client Services at (800\_)-522-2787. If cytogenetics tissue media is not available, collect in plain RPMI, Hanks solution, saline, or ringers. If specimen size is too large for a normal collection tube, a larger sterile container can be used such as a sterile urine cup and can be flooded with several tubes of cytogenetic tissue media. This test must be

ordered using Oncology test request form #43099 or through

turnaround times given represent average times, which are

your ARUP interface.



CPT Codes: 88239; 88264

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Refer to report. Refer to report

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Effective Date: May 20, 2024

Reference Interval:

By report



Chromosome Analysis, Lymph Node

2002300, CHR ONC	
Specimen Requirements:	
Patient Preparation:	
Collect:	Lymph node Any specimen type for oncology studies other than peripheral blood, bone marrow, and solid tumors. Thaw media prior to tissue inoculation. Collect cerebral spinal fluid (CSF), ocular fluid, and pleural fluid or other body fluids in a green (sodium heparin).
Specimen Preparation:	DO NOT FREEZE. Do not place in formalin. <u>Lymph nodes</u> <u>Tissues</u> : Transport 10 mm biopsy in a sterile, screw-top container filled with tissue culture transport media. Fluid: Transport 5 mL fluid in original collection tube.
Transport Temperature:	Room temperature.
Unacceptable Conditions:	Frozen specimens. <u>Lymph node</u> Tissue submitted in formalin.
Remarks:	This test must be ordered using Oncology test request form #43099 or through your ARUP interface.
Stability:	Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology:	Giemsa Band
Performed:	Sun-Sat
Reported:	3-10 days
Note:	These studies involve culturing of living cells; therefore, turnaround times given represent average times, which are subject to multiple variables. A processing fee will be charged if this procedure is canceled at the client's request after the test has been set up or if the specimen integrity is inadequate to allow culture growth. The fee will vary based on specimen type. Collect <a href="Iymph node biopsytissue">Iymph node biopsytissue</a> in a sterile, screw-top container filled with tissue culture transport medium (ARUP Supply #32788). Available online through eSupply using ARUP <a href="ConnectorConnect(TM">ConnectorConnect(TM)</a> or contact ARUP Client Services at (800-)-522-2787. If no transport media is available, collect in plain RPMI, Hanks solution, saline, or ringers. Contact ARUP Genetics Processing for other specimen types or information

Effective Date: May 20, 2024



and specific collection and transportation instructions.

Effective Date: May 20, 2024

CPT Codes: 88239; 88264

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Refer to report. Refer to report

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

By report



Mismatch Repair by Immunohistochemistry with Reflex to BRAF Codon 600 Mutation and MLH1 Promoter Methylation

Effective Date: May 20, 2024

2002327, MSI REFLEX

2002321, MSI NEFLEX	
Specimen Requirements:	
Patient Preparation:	
Collect:	Tumor tissue.
Specimen Preparation:	Tumor Tissue: Formalin fix (10 percent neutral buffered formalin is preferred) and paraffin embed tissue. If sending precut slides, do not oven bake. Transport tissue block or 15 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit (ARUP Supply #47808). Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at (800) 522-2787. (Min: 10 slides). Protect paraffin block and/or slides from excessive heat.
Transport Temperature:	Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Unacceptable Conditions:	Paraffin block with less than 25 percent tumor tissue. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens.
Remarks:	Include surgical pathology report. Submit electronic request. If you do not have electronic ordering capability, use an ARUP requisition form complete with an ARUP client number. For additional technical details, please contact ARUP Client Services at (800) 522-2787. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology:	Qualitative Immunohistochemistry (IHC)/Qualitative Real-Time Polymerase Chain Reaction
Performed:	Tue-Sat



Reported: 1-5 days Note: If MLH1 is abnormal for Mismatch Repair by IHC, then BRAF codon 600 will be added. If BRAF codon 600 is negative, MLH1 Promoter Methylation will be added. Additional charges apply. **CPT Codes:** 88342; 88341 x3; if reflexed, add 81210; if further reflexed, add 81288 New York DOH Approval Status: This test is New York DOH approved. Interpretive Data:

Effective Date: May 20, 2024

Refer to report.

Refer to the Colorectal Cancer or Lynch Syndrome topic at arupconsult.com.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.



PM/Scl-100 Antibody, IgG by Immunoblot 2003040, PM/SCL

Specimen Requirements:

**Patient Preparation:** 

Collect: Serum separator tube.

Specimen Preparation: Transfer 1 mL serum to an ARUP standard transport

tube. Standard Transport Tube. (Min: 0.3 mL)

Effective Date: May 20, 2024

Transport Temperature: Refrigerated.

Unacceptable Conditions: Plasma. Contaminated, hemolyzed, or severely lipemic

specimens.

Remarks:

Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2

weeks; Frozen: 1 month (avoid repeated freeze/thaw

cycles).year

Methodology: Qualitative Immunoblot

Performed: Tue, Thu, Sat

Reported: 1-4 days

Note:

CPT Codes: 86235

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although antibodies to other targets not detected by this assay may occur.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Negative





#### **TEST CHANGE**

B-Cell Clonality Screening (IgH and IgK) by PCR 2006193, BCELL SCRN

C i	Requirements:
Specimen	Remillements.
Opcomici	ricquircificitio.

**Patient Preparation:** 

Collect: Whole blood or bone marrow in lavender (EDTA), tissue,

formalin-fixed tissue.

**Specimen Preparation:** Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min:

> 1 mL) Bone Marrow: Do not freeze. Transport 3 mL bone marrow. (Min: 1 mL) Fresh Tissue: Freeze immediately. Transport 100 mg or 0.5-2.0 cm3 tissue. FFPE Tumor Tissue: Formalin -fixed (10 percent neutral buffered formalin) and paraffin -embedded tissue. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or four 10-micron shavings in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP

> Connect(TM) or contact ARUP Client Services at 800-522-2787.

Whole Blood, Bone Marrow: Refrigerated. Fresh Tissue: Transport Temperature:

> Frozen on dry ice. FFPE Tumor Tissue: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during

summer months.

**Unacceptable Conditions:** Plasma, serum. Specimens collected in anticoagulants other

> than EDTA. Clotted or grossly hemolyzed specimens. Tissue: FFPE specimens fixed/processed in any fixative other than 10 percent neutral buffered formalin. BoneDecalcified specimens

submitted in non-EDTA decalcifier.

If multiple specimens (blocks or slides) are sent to ARUP, they Remarks:

> must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until

clarification is provided.

Stability: Whole Blood or Bone Marrow: Refrigerated: 7 days; Frozen:

> Unacceptable Fresh Tissue: Ambient: Unacceptable; Refrigerated: 2 hours; Frozen: 1 year FFPE Tumor Tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen:

Unacceptable



Methodology: Capillary Electrophoresis/Polymerase Chain Reaction (PCR)

Performed: Varies

Reported: 5-9 days

Note: CPT Codes: 81261; 81264

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data: Refer to report.

Reference Interval:



# MYD88 L265P Mutation Detection by PCR, Quantitative 2009318 MYD88

2009318, MYD88	
Specimen Requirements:	
Patient Preparation:	
Collect:	Whole blood or bone marrow in lavender (EDTA) or FFPE tumor tissue.
Specimen Preparation:	Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL) Bone Marrow: Do not freeze. Transport 3 mL bone marrow. (Min: 1 mL) FFPE Tumor Tissue: Formalin _fixed (10 percent neutral buffered formalin) and paraffin _embedded tissue. Protect from excessive heat. Transport tissue in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787.
Transport Temperature:	Whole Blood, Bone Marrow: Refrigerated FFPE Tumor Tissue: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Unacceptable Conditions:	Plasma, serum. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens. FFPE Tumor Tissue: Specimens fixed in any fixative other than 10 percent neutral buffered formalin. <a href="BoneDecalcified">BoneDecalcified</a> specimens submitted in non-EDTA decalcifier.
Remarks:	If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Stability:	Whole Blood or Bone Marrow: Refrigerated: 7 days; Frozen: Unacceptable FFPE Tumor Tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology:	Real-Time Polymerase Chain Reaction
Performed:	Varies

Effective Date: May 20, 2024

## $A \ nonprofit\ enterprise\ of\ the\ University\ of\ Utah$ and its Department\ of\ Pathology

Effective Date: May 20, 2024

Reported:	5-10 days
Note:	
CPT Codes:	81305
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Refer to report.	
Reference Interval:	



Alcohol, Urine, Quantitative 2010136, CDCO ETOH

Specimen Requirements:

**Patient Preparation:** 

Collect: Random urine.

Specimen Preparation: Transfer 4 mL urine without additives or preservatives to an

ARUP Standard Transport Tube. (Min: 1 mL)

Effective Date: May 20, 2024

Transport Temperature: Room temperature.

**Unacceptable Conditions:** 

Remarks:

Stability: Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years (Avoid

repeated freeze/thaw cycles)

Methodology: Quantitative Gas Chromatography

Performed: Sun-Sat

Reported: 1-4 days

Note:

CPT Codes: 80320 (Alt code: G0480)

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Methodology: Quantitative Gas Chromatography with Flame Ionization Detection

Positive cutoff: 5 mg/dL

For medical purposes only; not valid for forensic use.

The absence of expected drug(s) and/or drug metabolite(s) may indicate inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:



## Effective August 17, 2015

Drugs Covered	Cutoff Concentrations
Ethanol	5 mg/dL
Ethyl Alcohol	5 mg/dL

HOTLINE NOTE: There is a numeric map change associated with this test. Refer to the Hotline Test Mix for interface build information.



Hereditary Hemolytic Anemia Panel Sequencing

2012052, HHA SEQ

Specimen Requirements:

**Patient Preparation:** 

Collect: Lavender (EDTA) or yellow (ACD solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL) New York State

Clients: Transport 5 mL whole blood. (Min: 3 mL)

Effective Date: May 20, 2024

Transport Temperature: Refrigerated.

**Unacceptable Conditions:** 

Remarks:

Stability: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen:

Unacceptable

Methodology: Massively Parallel Sequencing

Performed: Varies

Reported: 14-21 days

Note: Recent CBC result is required. GENES TESTED: AK1, ALDOA,

ANK1, CDAN1, CYB5R3, EPB41, EPB42, G6PD, GCLC, GPI, GSR, GSS, HK1, NT5C3A, PFKM, PGK1, PIEZO1, PKLR, SEC23B, SLC4A1, SLC01B1, SLC01B3, SPTA1, SPTB, TPI1, UGT1A1,

UGT1A6, UGT1A7

CPT Codes: 81443

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Refer to report. Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Reference Interval:



By report



Fibrillarin (U3 RNP) Antibody, IgG

2012173, U3 FIB

Specimen Requirements:

**Patient Preparation:** 

Collect: Serum separator tube.

Specimen Preparation: Transfer 1 mL serum to an ARUP <u>standard transport</u>

tube. Standard Transport Tube. (Min: 0.5 mL)

Effective Date: May 20, 2024

Transport Temperature: Refrigerated. Also acceptable: Frozen.

Unacceptable Conditions: Grossly hemolyzed or severely lipemic.

Remarks:

Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2

weeks; Frozen: 1 month (avoid repeated freeze/thaw

cycles).year

Methodology: Qualitative Immunoblot

Performed: Tue, Thu, Sat

Reported: 1-4 days

Note:

CPT Codes: 86235

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

The presence of fibrillarin (U3-RNP) IgG antibodies in association with an ANA IFA nucleolar pattern is suggestive of systemic sclerosis (SSc). In SSc, these antibodies are associated with distinct clinical features, such as younger age at disease onset, frequent internal organ involvement (pulmonary hypertension, myositis and renal disease). Fibrillarin antibodies are detected more frequently in African American patients with SSc compared to other ethnic groups. Strong correlation with ANA IFA results is recommended.

In a multiethnic multi-ethnic cohort of SSc patients (n=98), U3-RNP antibodies detected by immunoblot had an agreement of 98.9 percent with the gold standard immunoprecipitation (IP) assay. Approximately 71 percent (5/7) of the borderline U3-RNP results with ANA nucleolar pattern in this cohort were IP negative.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was



performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Negative



Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA 3000082, ANA IFA AB

Specimen Requirements:

**Patient Preparation:** 

Collect: Serum <u>separator tube</u> (SST).

Specimen Preparation: Separate from cells ASAP or within 2 hours of collection.

Transfer 1 mL serum to an ARUP <u>standard transport</u>

Effective Date: May 20, 2024

tube. Standard Transport Tube. (Min: 0.15 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Plasma. Contaminated, hemolyzed, or severely lipemic

specimens.

Remarks:

Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2

weeks; Frozen: 1 monthyear (avoid repeated freeze/thaw

cycles)

Methodology: Semi-Quantitative Indirect Fluorescent Antibody (IFA)

Performed: Sun-Sat

Reported: 1-3 days

Note: ANA identified by indirect fluorescence assay (IFA) using HEp-2

substrate and IgG-specific conjugate at a screening dilution of 1:80. Positive nuclear patterns reported include homogeneous, speckled, centromere, nucleolar, or nuclear dots. Positive cytoplasmic patterns reported include reticular/AMA, discrete/GW body-like, polar/golgi-like, rods and rings, or cytoplasmic speckled patterns. All positive results are reported

with endpoint titers at no additional charge.

CPT Codes: 86039

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Presence of antinuclear antibodies (ANA) is a hallmark feature of systemic autoimmune rheumatic diseases (SARD). However, ANA lacks diagnostic specificity and is associated with a variety of diseases (cancers, autoimmune, infectious, and inflammatory conditions) and may also occur in healthy individuals in varying prevalence. The lack of diagnostic specificity requires confirmation



of positive ANA by more specific serologic tests. ANA (nuclear reactivity) positive patterns reported include centromere, homogeneous, nuclear dots, nucleolar, or speckled. ANA (cytoplasmic reactivity) positive patterns reported include reticular/AMA, discrete/GW body-like, polar/golgi-like, cytoplasmic speckled or rods and rings. All positive patterns are reported to endpoint titers (1:2560). Reported patterns may help guide differential diagnosis, although they may not be specific for individual antibodies or diseases. Mitotic staining patterns not reported. Negative results do not necessarily rule out SARD.

Reference Interval:		
Less than 1:80		



Criteria Systemic Sclerosis Panel

3000479, SSC PANEL

Specimen Requirements:

**Patient Preparation:** 

Collect: Serum separator tube Separator Tube (SST).

Specimen Preparation: Separate from cells ASAP or within 2 hours of collection.

Transfer 3 mL serum to an ARUP standard transport

Effective Date: May 20, 2024

tube. Standard Transport Tube. (Min: 0.25 mL)

Transport Temperature: Refrigerated.

**Unacceptable Conditions:** Contaminated, hemolyzed, or severely lipemic specimens.

Remarks:

Stability: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 monthyear

(avoid repeated freeze/thaw cycles)

Semi-Quantitative Indirect Fluorescent Antibody/Semi-Methodology:

Quantitative Multiplex Bead Assay/Semi-Quantitative Enzyme-

Linked Immunosorbent Assay

Performed: Sun, Tue, Thu

Reported: 1-4 days

Note:

**CPT Codes:** 86039; 86235; 83516

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Component Scleroderma (Scl- 29 AU/mL or less 70) (ENA) Antibody, IgG

Interpretation Negative 30-40 AU/mL Equivocal 41 AU/mL or

greater Positive 19 Units or less

RNA Polymerase III Antibody, IgG

Negative 20-39 **Units Weak** Positive 40-80 Units Moderate Positive 81 Units or greater Strong Positive



Reference Interval:

Test Number	Components	Reference Interval
	Scleroderma (Scl-70) (ENA) Antibody, IgG	40 AU/mL or less
	RNA Polymerase III Antibody, IgG	19 Units or less
	Antinuclear Antibody (ANA), HEp-2, IgG	Less than 1:80



### FLT3 ITD and TKD Mutation Detection

3001161, FLT3-PCR

Specimen Requirements: **Patient Preparation:** Collect: Whole blood or bone marrow in lavender Lavender (EDTA). Also acceptable: Whole blood in ) or green (sodium heparin).) whole blood or bone marrow. **Specimen Preparation:** Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL) Bone Marrow: Do not freeze. Transport 3 mL bone marrow. (Min: 1 mL) Transport Temperature: Refrigerated. **Unacceptable Conditions:** Plasma, serum, FFPE tissue blocks/slides, or frozen tissue. Specimens collected in anticoagulants other than EDTA\_\_or sodium heparin. Clotted or grossly hemolyzed specimens. Remarks: Stability: Ambient: 24 hours; Refrigerated: 75 days; Frozen: Unacceptable Capillary Electrophoresis Methodology: Performed: Varies Reported: 2-7 days Note: **CPT Codes:** 81245; 81246 New York DOH Approval Status: This test is New York DOH approved. Interpretive Data: Refer to report. Reference Interval:



Multiple Myeloma Panel by FISH

3002063, FISHMMP

3002003, 1 131 IIVIIVIF	
Specimen Requirements:	
Patient Preparation:	
Collect:	Nondiluted Non-diluted bone marrow collected in a heparinized syringe. Also acceptable: whole blood collected in green Green (sodium heparin).
Specimen Preparation:	Transfer 3 mL bone marrow to a green (sodium heparin) (Min: 1 mL). OR transport 5 mL whole blood (green, sodium heparin) (Min: 2 mL). Additional specimen (recommend 2 mL) is required if concurrent testing (chromosome analysis and/or genomic microarray) is ordered due to the need to perform CD138+ cell enrichment process.
Transport Temperature:	Room temperature.
Unacceptable Conditions:	Frozen specimens. Paraffin-embedded specimens. Clotted specimens.
Remarks:	
Stability:	Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology:	Fluorescence in situ Hybridization (FISH)
Performed:	Sun-Sat
Reported:	5-14 days
Note:	Fluorescence in situ hybridization (FISH) panel is performed on CD138+ enriched sorted cells (assuming specimen is sufficient for enrichment sorting) for multiple myeloma prognosis-specific genomic abnormalities: 1p (CDKN2C loss/deletion)/1q (CKS1B) gain/amplification), /17p (TP53) loss/deletion)/ 17q (NF1). control, t(4;14) (IGH/FGFR3 or NSD2 (and MMSET) fusion), +9/9p (JAK2) enumeration, t(11;14) (IGH/CCND1 fusion and/or +11), t(14;16) (IGH/MAF fusion), t(14;20) (IGH/MAFB fusion). When this test is ordered in conjunction with a chromosome analysis, and/or genomic microarray, specimen prioritization for low cellularity samples will be given to FISH>microarray-karyotype due to for the need for CD138+ cell enrichment prior to FISH and microarray testing sorting of CD138+ cells. This could impact the successful completion of

A nonprofit enterprise of the University of Utah and its Department of Pathology

lower priority tests.the chromosome analysis. If enrichmentsorting fails to yield sufficient CD138+ cells, testing will be performed using unenrichedunsorted cells, if available. A processing fee will be charged if this procedure is canceled at the client's request, after the test has been set up, or if the specimen integrity is inadequate to allow a complete analysis. This test must be ordered using Oncology test request form #43099 or through your ARUP interface. Contact ARUP Genetics Processing for other specimen types or information and specific collection and transportation instructions.

Effective Date: May 20, 2024

CPT Codes: 88271 x7; 88275 x7

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

By report

**Deleted Cells** 



Monoclonal Protein Study, 24 hour, Urine

3002105, U-PEP

Specimen Requirements:

**Patient Preparation:** 

Collect: 24-hour urine. Refrigerate during collection. Also acceptable:

Random urine specimens and urine supernate.

Specimen Preparation: Transfer two 4 mL aliquots from well-mixed 24 hour collection

to individual ARUP standard transport tubes. (Min: 4 mL)

Effective Date: May 20, 2024

Transport Temperature: Refrigerated.

**Unacceptable Conditions:** 

Remarks: Record total volume and collection time interval on transport

tube and test request form.

Stability: Ambient: 24 hours ; Refrigerated: 1 week; Frozen: 1 month

Methodology: Semi-Quantitative Electrophoresis/Qualitative Gel

Electrophoresis/ Quantitative Spectrophotometry

Performed: <u>Sun-Sat Mon-Fri</u>

Reported: 1-5 days

Note:

CPT Codes: 84156; 84166; 86335

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Total urine protein measurement using this method characteristically underestimates urinary light chains.

Reference Interval:

Test Number	· · · · · · · · · · · · · · · · · ·	Reference Interval
	IFE Interpretation	By report
	Urine 24 Hour Protein	40-150 mg/d

HOTLINE NOTE: There is a component change associated with this test. One or more components have been added or removed. Refer to the Hotline Test Mix for interface build information.





IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4

Effective Date: May 20, 2024

3002134, IDH1 RFLX

3002134, IDH1 KFLX	
Specimen Requirements:	
Patient Preparation:	
Collect:	Tumor tissue.
Specimen Preparation:	Formalin fix (10 percent neutral buffered formalin is preferred) and paraffin embed specimen. Protect paraffin block and/or slides from excessive heat. Transport tissue block or 7 unstained (5-micron thick sections), positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at (800)522-2787. (Min. 4 slides) If sending precut slides, do not oven bake.
Transport Temperature:	Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Unacceptable Conditions:	Paraffin block with less than 25 percent tumor tissue. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens.
Remarks:	Include surgical pathology report. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology:	Immunohistochemistry
Performed:	Mon-Fri
Reported:	1-5 days

BORATORIES

Note: This test code includes pathologist interpretation. Negative

IHC results will reflex to IDH1 and IDH2 Mutation Analysis, Exon 4, to assess for less common IDH mutations. Additional

Effective Date: May 20, 2024

charges apply.

CPT Codes: 88342; if reflexed, add 81120; 81121

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Refer to report.

Reference Interval:

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.



1p19q Deletion by FISH and IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4

Effective Date: May 20, 2024

3002135, OLIGO PAN

Specimen Requirements:	
Patient Preparation:	
Collect:	Tumor tissue.
Specimen Preparation:	Formalin fix (10 percent neutral buffered formalin is preferred) and paraffin embed specimen. Protect paraffin block and/or slides from excessive heat. Transport tissue block or 10 unstained (5-micron thick sections), positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at (800)522-2787. (Min. 6 slides) If sending precut slides, do not oven bake.
Transport Temperature:	Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Unacceptable Conditions:	Paraffin block with less than 25 percent tumor tissue. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens.
Remarks:	Include surgical pathology report. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology:	Fluorescence in situ Hybridization (FISH)/Immunohistochemistry/Polymerase Chain Reaction/Sequencing
Performed:	Mon-Fri

Reference Interval:

Reported:

1-7 days

This test code includes pathologist interpretation. Negative IDH1 IHC results will reflex to IDH1 and IDH2 Mutation Analysis, Exon 4, to assess for less common IDH mutations. Additional charges apply.

CPT Codes:

88342; 88377 x2; if reflexed, add 81120; 81121

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Refer to report.

Effective Date: May 20, 2024

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.



## Autoimmune Liver Disease Reflexive Panel

3002479, LIVER PAN	
Specimen Requirements:	
Patient Preparation:	
Collect:	Serum <u>separator tube</u> Separator Tube (SST).
Specimen Preparation:	Separate from cells ASAP or within 2 hours of collection. Transfer 1.5 mL serum to an ARUP <u>standard transport</u> <u>tube.</u> Standard Transport Tube. (Min: 1.0 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Nonserum Non-serum, heat-inactivated, contaminated, grossly icteric, severely lipemic, grossly hemolyzed specimens, or inclusion of fibrin clot.
Remarks:	
Stability:	After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 monthyear (avoid repeated freeze/thaw cycles)
Methodology:	Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)//Semi-Quantitative Indirect Fluorescent Antibody (IFA)
Performed:	Sun-Sat
Reported:	1-8 days
Note:	If F-Actin, IgG by ELISA is 20 Units or greater, then Smooth Muscle Antibody (SMA), IgG by IFA titer will be added. Additional charges apply. ANA identified by indirect fluorescence assay (IFA) using HEp-2 substrate and IgG-specific conjugate at a screening dilution of 1:80. Positive nuclear patterns reported include homogeneous, speckled, centromere, nucleolar, or nuclear dots. Positive cytoplasmic patterns reported include reticular/AMA, discrete/GW body-like, polar/golgi-like, rods and rings, or cytoplasmic speckled patterns. All positive results are reported with endpoint titers at no additional charge.
CPT Codes:	86381; 83516; 86376; 86015; 86039; if reflexed, add 86256
New York DOH Approval Status:	This test is New York DOH approved.



Interpretive Data: Interpretation Component Mitochondrial M2 20.0 Units or less Negative 20.1-Antibody, IgG (ELISA) 24.9 Units Equivocal 25.0 Units or greater Positive Soluble Liver 0.0-20.0 U Antigen Antibody, Negative 20.1-IgG 24.9 U Equivocal Greater than or equal to 25.0 U Positive 0.0-20.0 U Liver-Kidney Microsome - 1 Negative 20.1-Antibody, IgG 24.9 U Equivocal 25.0 U or greater Positive F-Actin (Smooth 19 Units or less Muscle) Ab, IgG Negative 20 - 30 by ELISA **Units Weak** Positive-Suggest repeat testing in two to three weeks with fresh specimen. 31 Units or greater Positive-Suggestive of autoimmune

Effective Date: May 20, 2024

#### Reference Interval:

hepatitis type 1 or chronic active hepatitis.

Test Number	Components	Reference Inte	rval
	Mitochondrial (M2) Antibody, IgG	24.9 Units or le	ess
	Soluble Liver Antigen Antibody, IgG	24.9 U or less	
	Liver-Kid Microsome-1 Ab, IgG by ELISA	24.9 U or less	
	F-Actin (Smooth Muscle) Ab, IgG by ELISA	19 Units or les	s
	F-Actin (Smooth Muscle) Ab, IgG by ELISA		
		19 Units or less	Negative
		20-30 Units	Weak Positive - Suggest repeat testing in two to three weeks with a fresh specimen.
		31 Units or greater	Positive - Suggestive of autoimmune hepatitis or chronic active



Antinuclear Antibody (ANA), HEp-2, IgG Less than 1:80	



## Fatty Acids Profile, Essential in Red Blood Cells

3003086, FA PRO RBC

Specimen Requirements:	
Patient Preparation:	
Collect:	Green (sodium heparin), lavender (K2EDTA), or yellow (ACD solution A).  Green (Sodium Heparin), Lavender (K2EDTA), Yellow (ACD Solution A), or Protease Inhibitor tube (PPACK; Phe-Pro-Arg-chloromethylketone) (ARUP supply #49662), available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at (800) 522-2787. A winged collection set must be used.
Specimen Preparation:	DO NOT FREEZE. Transport 6 mL whole blood. (Min: 2 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Gross hemolysis, frozen whole blood.
Remarks:	Patient age is required on the test request form. Include information regarding treatment, family history, and tentative diagnosis.
Stability:	Ambient: 24 hours; Refrigerated: 7 days; Frozen: Unacceptable
Methodology:	Gas Chromatography-Mass Spectrometry (GC-MS)
Performed:	Varies
Reported:	7-10 days
Note:	
CPT Codes:	82542
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
This test does not screen for disor	ders of peroxisomal biogenesis/function.
Reference Interval:	
By Report	





# Microsatellite Instability (MSI) HNPCC/Lynch Syndrome by PCR 3004277, MSIPCR

Specimen Requirements:	
Patient Preparation:	
Collect:	Tumor AND normal epithelial tissue.
Specimen Preparation:	Tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block(s) or 10 unstained 5-micron slides (5 tumor and 5 normal epithelial). Transport block(s) and/or slide(s) in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect (TM) or contact ARUP Client Services at 800-522-2787.
Transport Temperature:	Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months
Unacceptable Conditions:	Less than 25 percent tumor or less than 50 percent normal epithelial tissue. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Bone Decalcified specimens submitted in non-EDTA decalcifier.
Remarks:	Include surgical pathology report. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology:	Capillary Electrophoresis/Polymerase Chain Reaction (PCR)
Performed:	Varies
Reported:	10-20 days
Note:	

CPT Codes: 81301

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:
Refer to report.

Reference Interval:



# MLH1 Promoter Methylation 3004308, MLH1 PCR

3004300, MEITI FOR	
Specimen Requirements:	
Patient Preparation:	
Collect:	Tumor tissue.
Specimen Preparation:	Tumor Tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 5 unstained 5-micron slides. Transport block and/or slide(s) in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787.
Transport Temperature:	Room temperature. Also Acceptable: Refrigerated. Ship in cooled container during summer months.
Unacceptable Conditions:	<u>Less than 25 percent tumor.</u> Specimens fixed in any fixative other than 10 percent neutral buffered formalin. <del>Less than 25 percent tumor.</del> <u>Bone Decalcified</u> specimens <u>submitted in non-EDTA decalcifier</u> .
Remarks:	Include surgical pathology report. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology:	Real-Time Polymerase Chain Reaction/Fluorescence Resonance Energy Transfer (FRET)
Performed:	Varies
Reported:	7-12 days
Note:	

CPT Codes:	81288
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Refer to report.	
Reference Interval:	



### MGMT Promoter Methylation Detection by ddPCR

3005956, MGMT METH	
Specimen Requirements:	
Patient Preparation:	
Collect:	Tumor tissue.
Specimen Preparation:	Tumor Tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 5 unstained 5-micron slides. Transport block and/or slide(s) in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787.
Transport Temperature:	Room temperature. Ship in cooled container during summer months.
Unacceptable Conditions:	Less than 25 percent tumor. Specimens fixed in any fixative other than 10 percent neutral buffered formalin.  Bone Decalcified specimens. Less than 25 percent tumor. submitted in non-EDTA decalcifier.
Remarks:	Include surgical pathology report. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology:	Droplet Digital PCR (ddPCR)
Performed:	Varies
Reported:	8-12 days
Note:	

CPT Codes:	81287
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Refer to report.	
Reference Interval:	



NEW TEST - Available Now

**Click for Pricing** 

B-Cell CD20 Expression by Flow Cytometry, Quantitative

3016431, CD20 QUANT

3016431, CD20 QUANT	
Specimen Requirements:	
Patient Preparation:	
Collect:	Green (sodium heparin). Also acceptable: lavender (EDTA) or pink (K2EDTA).
Specimen Preparation:	Transport 5 mL whole blood. (Min: 1 mL). Do not freeze.
Transport Temperature:	Preferred transport temp: Room temperature. Also acceptable: Refrigerated. Specimen should be received within 72 hours of collection for optimal viable testing.
Unacceptable Conditions:	Clotted, hemolyzed, or frozen specimens. Specimens received more than 72 hours from collection.
Remarks:	Clinical history, differential diagnosis, and any relevant pathology reports.
Stability:	Ambient: 72 hours; Refrigerated: 72 hours; Frozen: Unacceptable.
Methodology:	Flow Cytometry
Methodology: Performed:	Flow Cytometry Sun-Sat
Performed:	Sun-Sat
Performed: Reported:	Sun-Sat  1-2 days  Monoclonal antibody-based therapies, such as rituximab that target the CD20 antigen, are being used to treat patients with avariety of autoimmune disorders. The effectiveness of this therapy is dependent on the degree of B-cell suppression andvaries by disease state. This assay is designed to detect low levels of B cells and provide quantitative cell numbers in thesetting of rituximab-treated patients using both CD20 and
Performed: Reported: Note:	Sun-Sat  1-2 days  Monoclonal antibody-based therapies, such as rituximab that target the CD20 antigen, are being used to treat patients with avariety of autoimmune disorders. The effectiveness of this therapy is dependent on the degree of B-cell suppression andvaries by disease state. This assay is designed to detect low levels of B cells and provide quantitative cell numbers in thesetting of rituximab-treated patients using both CD20 and CD19.

Reference Interval:		
Refer to report.		

Effective Date: May 20, 2024

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.



### **NEW TEST - Available Now**

### **Click for Pricing**

# Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel 3017050, RAPID AML

On a sine an Danwinson and	
Specimen Requirements:	
Patient Preparation:	
Collect:	Lavender (whole blood or bone marrow collected in EDTA), green (peripheral blood or bone marrow collected in sodium heparin)
Specimen Preparation:	Whole Blood or Bone Marrow: Transport 2 mL (Min: 1.0 mL)
Transport Temperature:	Whole Blood or Bone Marrow: Refrigerated.
Unacceptable Conditions:	Serum, plasma, grossly hemolyzed specimens, buccal brush or swab, FFPE tissue, or frozen samples.
Remarks:	
Stability:	Whole blood: Ambient: 1 week, Refrigerated: 2 weeks, Frozen: Unacceptable Bone marrow: Ambient: 72 hours, Refrigerated: 1 week, Frozen: Unacceptable
Methodology:	Massively Parallel Sequencing
Performed:	Varies
Reported:	3-7 days
Note:	The following regions are targeted to detect clinically relevant hotspot mutations, unless otherwise indicated: CEBPA* (NM_004364) exon 1; FLT3 (NM_004119) exons 14, 15, 16, 20; IDH1 (NM_005896) exon 4; IDH2 (NM_002168) exon 4; KIT (NM_000222) exons 8, 9, 10, 11, 17; KRAS (NM_004985) exons 2, 3, 4; NPM1 (NM_002520) exon 11; NRAS (NM_002524) exons 2, 3, 4; TP53*(NM_000546) all coding exons *CEBPA and TP53 are fully covered; any clinically relevant or potentially relevant variants will be reported. More information about the targeted regions of this test is included in the Additional Technical Information.
CPT Codes:	81450
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Interpretive Data:	
Refer to report.	
Reference Interval:	

Effective Date: May 20, 2024

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.



**NEW TEST - Available Now** 

Click for Pricing

Adiponectin, Quantitative Serum/Plasma

3017195, ADIP SP

Specimen Requirements:

**Patient Preparation:** 

Collect: Serum separator tube (SST), light green (lithium heparin with

gel separator), or plain red.

Specimen Preparation: Allow serum to clot for 15-20 minutes at room temperature.

Separate serum or plasma from cells ASAP or within 2 hours of

Effective Date: May 3, 2024

collection. Transfer 0.5 mL serum or plasma to an ARUP

standard transport tube. (Min: 0.2 mL)

Transport Temperature: Frozen

Unacceptable Conditions: EDTA plasma.

Remarks:

Stability: After separation from cells: Ambient: 2 days; Refrigerated: 1

week; Frozen: 1 month

Methodology: Quantitative Radioimmunoassay (RIA)

Performed: Wed

Reported: 1-8 days

Note:

CPT Codes: 83519

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Reference Interval:

Effective Date: May 3, 2024



Age Male (ug/mL) Female(ug/mL) 0-7 years 2.33-26.5 2.33-26.5 8-9 years 3.96-14.9 3.96-14.9 10-11 years 3.36-13.8 3.36-13.8 12-13 years 4.50-13.2 4.50-13.2 14-15 years 3.67-13.7 3.67-13.7 16-19 years 2.74-13.3 2.74-13.3 greater than 19 2.00-13.9 4.00-19.4 years

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.



**NEW TEST - Available Now** 

**Click for Pricing** 

**BRAF Mutation Detection** 

3017203, BRAF NGS

Specimen Requirements:

**Patient Preparation:** 

Collect: Tumor tissue.

Specimen Preparation: Tumor Tissue: Formalin fix (10 percent neutral buffered

> formalin, not decalcified) and paraffin embedded tissue with at least 20 percent tumor burden. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 8 unstained 5 micron slides. (Min: 5 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP

Effective Date: May 3, 2024

Connect Contact ARUP Client Services at 800-522-2787.

Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in

cooled container during summer months.

**Unacceptable Conditions:** Less than 20 percent tumor. Specimens fixed in any fixative

> other than 10 percent neutral buffered formalin. Decalcified specimens (except in EDTA). Decalcified specimens in EDTA

will require a client approved disclaimer.

Remarks: Include surgical pathology report. If multiple specimens

> (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most

> appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification

> determine if there is an adequate tumor area for testing. Submitted specimens should contain >20 percent tumor. Specimens may be canceled, and a new block requested if there is not an acceptable area for extraction or if block/tissue has been decalcified (except in EDTA). Samples that produce

is provided. Our pathologists will review every case to

less than the optimal concentration of DNA input and/or samples decalcified in EDTA will require a disclaimer for testing

or be canceled.

Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen:



Unacceptable

5 is evaluated to detect hotspot Technical Information for more

New York DOH Approval Status:

Specimens from New York clients will be sent out to a New

Effective Date: May 3, 2024

York DOH approved laboratory, if possible.

Interpretive Data:

Reference Interval:

Test	Components	Reference Interval
Number		

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.



### **NEW TEST - Available Now**

### **Click for Pricing**

## BRAF Mutation Detection with Reflex to MLH1 Promoter Methylation 3017204 BRAF BEEL

3017204, BRAF REFL	
Specimen Requirements:	
Patient Preparation:	
Collect:	Tumor tissue
Specimen Preparation:	Tumor Tissue: Formalin fix (10 percent neutral buffered formalin, not decalcified) and paraffin embedded tissue with at least 25 percent tumor burden. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 8 unstained 5 micron slides. (Min: 5 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP Connectcontact ARUP Client Services at 800-522-2787. New York State Clients: Transport tissue (Formalin-fixed, paraffin embedded) or 10 unstained, nonbaked slides and 1 slide stained with hematoxylin and eosin.
Transport Temperature:	Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Unacceptable Conditions:	Less than 25 percent tumor. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens (except in EDTA). Decalcified specimens in EDTA will require a client approved disclaimer.
Remarks:	Include surgical pathology report. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided. Our pathologists will review every case to determine if there is an adequate tumor area for testing. Submitted specimens should contain >25 percent tumor. Specimens may be canceled, and a new block requested if there is not an acceptable area for extraction or if block/tissue has been decalcified (except in EDTA). Samples that produce less than the optimal concentration of DNA input and/or samples decalcified in EDTA will require a disclaimer for testing



or be canceled. Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable Methodology: Massively Parallel Sequencing Performed: Varies Reported: 10-15 days BRAF (NM\_004333) exon 15 is evaluated to detect hotspot Note: mutations. If BRAF V600E mutation is not detected, then MLH1 Promoter Methylation will be added. Additional charges apply. See Additional Technical Information for more information. **CPT Codes:** 81210; If reflexed, add 81288 New York DOH Approval Status: Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible. Interpretive Data: Reference Interval: Test Components Reference Interval Number

Effective Date: May 3, 2024

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.



**NEW TEST - Available Now** 

Click for Pricing

Colorectal Cancer Mutation Panel

3017209, CRC MUT

Specimen	Requirements	٠
ODCCIIICII	I ICUUII CITICITIS	

**Patient Preparation:** 

Collect: Tumor tissue

Specimen Preparation: Tumor Tissue: Formalin fix (10 percent neutral buffered

> formalin, not decalcified) and paraffin embedded tissue with at least 20 percent tumor burden. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 8 unstained 5 micron slides. (Min: 5 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP

Effective Date: May 3, 2024

Connect Contact ARUP Client Services at 800-522-2787.

Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in

cooled container during summer months.

**Unacceptable Conditions:** Less than 20 percent tumor. Specimens fixed in any fixative

> other than 10 percent neutral buffered formalin. Decalcified specimens (except in EDTA). Decalcified specimens in EDTA

will require a client approved disclaimer.

Remarks: Include surgical pathology report. If multiple specimens

> (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual

> orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification

is provided. Our pathologists will review every case to

determine if there is an adequate tumor area for testing. Submitted specimens should contain >20 percent tumor. Specimens may be canceled, and a new block requested if there is not an acceptable area for extraction or if block/tissue has been decalcified (except in EDTA). Samples that produce less than the optimal concentration of DNA input and/or

samples decalcified in EDTA will require a disclaimer for testing

or be canceled.

Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen:



Unacceptable

Performed: Varies

Reported: 10-15 days

Note: Hotspots Tested: BRAF (NM\_004333) exon 15; KRAS

(NM\_004985) exons 2, 3, 4; NRAS (NM\_002524) exons 2, 3, 4. See Additional Technical Information for more information.

Effective Date: May 3, 2024

CPT Codes: 81210, 81275, 81276, 81311

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Reference Interval:

Test	Components	Reference Interval
Number		



Click for Pricing

IDH1 and IDH2 Mutation Detection

3017222, IDH1-IDH2

•	_		_
Snaciman	RAC	IIIIΓΔΓ	nante:
Specimen	1166	unci	nento.

**Patient Preparation:** 

Collect: Tumor tissue

Specimen Preparation: Tumor Tissue: Formalin fix (10 percent neutral buffered

formalin, not decalcified) and paraffin embedded tissue with at least 20 percent tumor burden. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 8 unstained 5 micron slides. (Min: 5 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP Connectcontact ARUP Client Services at 800-522-2787. New York State Clients: Transport tissue (Formalin-fixed, paraffin embedded) or 10 unstained, nonbaked slides and 1 slide

Effective Date: May 3, 2024

stained with hematoxylin and eosin.

Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in

cooled container during summer months.

Unacceptable Conditions: Less than 20 percent tumor. Specimens fixed in any fixative

other than 10 percent neutral buffered formalin. Decalcified specimens (except in EDTA). Decalcified specimens in EDTA

will require a client approved disclaimer.

Remarks: Include surgical pathology report. If multiple specimens

(blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to

orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided. Our pathologists will review every case to determine if there is an adequate tumor area for testing.

Submitted specimens should contain >20 percent tumor.

Specimens may be canceled, and a new block requested if there is not an acceptable area for extraction or if block/tissue has been decalcified (except in EDTA). Samples that produce less than the optimal concentration of DNA input and/or

samples decalcified in EDTA will require a disclaimer for testing



Effective Date: May 3, 2024

	or be canceled.	
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable	
Methodology:	Massively Parallel Sequencing	
Performed:	Varies	
Reported:	10-15 days	
Note:	Hotspots Tested: IDH1 (NM_005896) exon 4 and IDH2 (NM_002168) exon 4. See Additional Technical Information for more information.	
CPT Codes:	81120; 81121	
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.	
Interpretive Data:		
Reference Interval:		
Test Components Number	Reference Interval	



Click for Pricing

Lung Cancer Mutation Panel 3017230, LUNG MUT

Specimen Requirements:

**Patient Preparation:** 

Collect: Tumor tissue

Specimen Preparation: Tumor Tissue: Formalin fix (10 percent neutral buffered

formalin, not decalcified) and paraffin embedded tissue with at least 20 percent tumor burden. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 8 unstained 5 micron slides. (Min: 5 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP Connectcontact ARUP Client Services at 800-522-2787. New York State Clients: Transport tissue (Formalin-fixed, paraffin embedded) or 10 unstained, nonbaked slides and 1 slide

Effective Date: May 3, 2024

stained with hematoxylin and eosin.

Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in

cooled container during summer months.

Unacceptable Conditions: Less than 20 percent tumor. Specimens fixed in any fixative

other than 10 percent neutral buffered formalin. Decalcified specimens (except in EDTA). Decalcified specimens in EDTA

will require a client approved disclaimer.

Remarks: Include surgical pathology report. If multiple specimens

(blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual

Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification

orders for each sample submitted. A Pathologist Block

is provided. Our pathologists will review every case to

determine if there is an adequate tumor area for testing. Submitted specimens should contain >20 percent tumor. Specimens may be canceled, and a new block requested if there is not an acceptable area for extraction or if block/tissue has been decalcified (except in EDTA). Samples that produce

less than the optimal concentration of DNA input and/or samples decalcified in EDTA will require a disclaimer for testing



Effective Date: May 3, 2024

	or be canceled.	
Stability:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable	
Methodology:	Massively Parallel Sequencing	
Performed:	Varies	
Reported:	10-15 days	
Note:	Hotspots Tested: BRAF (NM_004333) exon 15; EGFR (NM_005228) exons 18, 19, 20, 21; ERBB2 (NM_004448) exons 8, 19, 20; KRAS (NM_004985) exons 2, 3, 4; MET (NM_001127500) exons 14, 15. See Additional Technical Information for more information.	
CPT Codes:	81445, 81235, 81210, 81275, 81276	
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.	
Interpretive Data:		
Reference Interval:		
Test Components Number	Reference Interval	



**Click for Pricing** 

Melanoma Mutation Panel

3017233, MEL MUT

Specimen Requirements:

**Patient Preparation:** 

Collect: Tumor tissue

Specimen Preparation: Tumor Tissue: Formalin fix (10 percent neutral buffered

formalin, not decalcified) and paraffin embedded tissue with at least 20 percent tumor burden. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 8 unstained 5 micron slides. (Min: 5 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP Connectcontact ARUP Client Services at 800-522-2787. New York State Clients: Transport tissue (Formalin-fixed, paraffin embedded) or 10 unstained, nonbaked slides and 1 slide

Effective Date: May 3, 2024

stained with hematoxylin and eosin.

Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in

cooled container during summer months.

Unacceptable Conditions: Less than 20 percent tumor. Specimens fixed in any fixative

other than 10 percent neutral buffered formalin. Decalcified specimens (except in EDTA). Decalcified specimens in EDTA

will require a client approved disclaimer.

Remarks: Include surgical pathology report. If multiple specimens

(blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block

Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided. Our pathologists will review every case to

determine if there is an adequate tumor area for testing. Submitted specimens should contain >20 percent tumor. Specimens may be canceled, and a new block requested if there is not an acceptable area for extraction or if block/tissue has been decalcified (except in EDTA). Samples that produce less than the optimal concentration of DNA input and/or

samples decalcified in EDTA will require a disclaimer for testing



Effective Date: May 3, 2024

Test Number	Components	Reference Interval	
Interpretive Data:  Reference Interval:			
New York DOH Approval Status:		Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.	
CPT Codes:		81210, 81272; 81275; 81276, 81311	
Note:		Hotspots Tested: BRAF (NM_004333) exon 15; KIT (NM_000222) exons 9, 11, 13, 14, 17, 18; KRAS (NM_004985) exons 2, 3, 4; NRAS (NM_002524) exons 2, 3, 4. See Additional Technical Information for more information.	
Reporte	d:	10-15 days	
Perform	ed:	Varies	
Method	ology:	Massively Parallel Sequencing	
Stabi	ility:	Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable	
		or be canceled.	



**Click for Pricing** 

**TPMT Genotyping** 

3017372, TPMTGENO

Specimen Requirements:

**Patient Preparation:** 

Collect: Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or

B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)

Transport Temperature: Refrigerated

Unacceptable Conditions: Plasma or serum; specimens collected in sodium heparin or

lithium heparin; frozen specimens in glass collection tubes;

Effective Date: May 20, 2024

frozen yellow (ACD solution A or B)

Remarks:

Stability: Room temperature: 72 hours; Refrigerated: 1 week; Frozen: 1

month

Methodology: Polymerase Chain Reaction (PCR)/Flourescence Monitoring

Performed: Varies

Reported: 5-10 days

Note: Whole blood is the preferred specimen. Saliva samples that

yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-

determined criteria for reporting.

CPT Codes: 81335

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Refer to report.

Counseling and informed consent are recommended for genetic testing. Consent forms are

available online.

Reference Interval:

By report



Effective Date: May 20, 2024



**Click for Pricing** 

NUDT15 Genotyping

3017373, NUDT15GENO

Specimen Requirements:

**Patient Preparation:** 

Collect: Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or

B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)

Transport Temperature: Refrigerated

Unacceptable Conditions: Plasma or serum; specimens collected in sodium heparin or

lithium heparin; frozen specimens in glass collection tubes;

Effective Date: May 20, 2024

frozen yellow (ACD solution A or B)

Remarks:

Stability: Room temperature: 72 hours; Refrigerated: 1 week; Frozen: 1

month

Methodology: Polymerase Chain Reaction (PCR)/Fluorescence Monitoring

Performed: Varies

Reported: 5-10 days

Note: Whole blood is the preferred specimen. Saliva samples that

yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-

determined criteria for reporting.

CPT Codes: 81306

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Refer to report.

Counseling and informed consent are recommended for genetic testing. Consent forms are

available online.

Reference Interval:

By report



Effective Date: May 20, 2024



**Click for Pricing** 

TPSAB1 Copy Number Analysis by ddPCR

3017399, TPSAB1

Specimen Requirements:

**Patient Preparation:** 

Collect: Whole blood or bone marrow in lavender (EDTA) preferred. Also

acceptable: Green (sodium heparin)

Specimen Preparation: Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min:

1 mL) Bone Marrow: Do not freeze. Transport 3 mL bone

Effective Date: May 3, 2024

marrow. (Min: 1 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Plasma, serum, FFPE tissue blocks/slides, or fresh or frozen

tissue. Specimens collected in anticoagulants other than EDTA

(purple) or sodium heparin (green). Clotted or grossly

hemolyzed specimens.

Remarks:

Stability: Refrigerated: 7 days; Frozen: Unacceptable

Methodology: Droplet Digital PCR (ddPCR)

Performed: Varies

Reported: 10-14 days

Note:

CPT Codes: 81479

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Refer to report.

Reference Interval:



**Click for Pricing** 

Ma2/Ta Antibody, IgG by Immunoblot, CSF

3017440, MA2/TA CSF

Specimen Requirements:

**Patient Preparation:** 

Collect: CSF

Specimen Preparation: Transfer 1 mL CSF to an ARUP standard transport tube. (Min:

Effective Date: May 20, 2024

0.60 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Urine, plasma. Contaminated, heat-inactivated, hemolyzed, or

lipemic specimens.

Remarks:

Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2

weeks; Frozen: 1 month

Methodology: Qualitative Immunoblot

Performed: Mon, Thu, Sat

Reported: 1-4 days

Note:

CPT Codes: 84182

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

IgG antibodies to Ma2/Ta are associated with paraneoplastic neurologic syndromes with phenotypes most often including a combination of limbic encephalitis, diencephalic encephalitis, and brainstem encephalitis. Patients with anti-Ma2/Ta paraneoplastic neurologic syndromes should be thoroughly evaluated for cancer, including testicular cancer and adenocarcinoma, as neurologic symptoms often precede cancer diagnosis. Use of immune checkpoint inhibitors has also been associated with an increased risk of anti-Ma2 paraneoplastic neurologic disease. Consider sending testing in serum as well as CSF to improve diagnostic yield. Results (positive or negative) should be interpreted in the context of the patient's complete clinical picture, as false positives may occur and a negative result does not exclude the diagnosis of paraneoplastic neurologic disease.

Reference Interval:



Test Components
Number

Ma2/Ta Antibody, IgG by Immunoblot, CSF

Reference Interval

Negative

Effective Date: May 20, 2024



### **Click for Pricing**

### Ma2/Ta Antibody, IgG by Immunoblot, Serum

3017441, MA2/TA SER

Specimen Requirements:

**Patient Preparation:** 

Collect: Serum separator tube.

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection.

Transfer 1 mL serum to an ARUP standard transport tube. (Min:

Effective Date: May 20, 2024

0.30 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Plasma. Contaminated, heat-inactivated, hemolyzed, or lipemic

specimens.

Remarks:

Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2

weeks; Frozen: 1 month

Methodology: Qualitative Immunoblot

Performed: Mon, Thu, Sat

Reported: 1-4 days

Note:

CPT Codes: 84182

New York DOH Approval Status: This test is New York DOH approved.

### Interpretive Data:

IgG antibodies to Ma2/Ta are associated with paraneoplastic neurologic syndromes with phenotypes most often including a combination of limbic encephalitis, diencephalic encephalitis, and brainstem encephalitis. Patients with anti-Ma2/Ta paraneoplastic neurologic syndromes should be thoroughly evaluated for cancer, including testicular cancer and adenocarcinoma, as neurologic symptoms often precede cancer diagnosis. Use of immune checkpoint inhibitors has also been associated with an increased risk of anti-Ma2 paraneoplastic neurologic disease. Consider sending testing in CSF as well as serum to improve diagnostic yield. Results (positive or negative) should be interpreted in the context of the patient's complete clinical picture, as false positives may occur and a negative result does not exclude the diagnosis of paraneoplastic neurologic disease.

Reference Interval:



Test Components Reference Interval

Ma2/Ta Antibody, IgG by Immunoblot, Ser Negative

Effective Date: May 20, 2024



**Click for Pricing** 

HLA-B51 Genotyping, Behcet Disease

3017549, HLA B51

Specimen Requirements:

**Patient Preparation:** 

Collect: Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or

B).

Specimen Preparation: Transport 5 mL whole blood. (Min: 3 mL).

Transport Temperature: Refrigerated

Unacceptable Conditions: Specimens collected in green (sodium or lithium heparin).

Remarks:

Stability: Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Methodology: Polymerase Chain Reaction/Massively Parallel

Sequencing/Sequence-Specific Oligonucleotide Probe

Effective Date: May 3, 2024

Hybridization

Performed:

Reported: 8-15 days

Note:

CPT Codes: 81381

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Background Information for HLA-B51 Genotyping for Behcet Disease:

Characteristics: Behcet disease (BD) is a multisystem chronic inflammatory disease, caused by vasculitis of arteries and veins of all sizes, involving the skin, mucosa, eyes, joints, cardiovascular, gastrointestinal, and nervous systems.

Prevalence: BD shows worldwide distribution, but it is most common in the Mediterranean basin, Middle East, and East Asian countries. Prevalence is high in Iran and Turkey with 80-370 cases/100,000 individuals, and comparatively low in the U.S. with 5.2 cases/100,000 individuals.

Inheritance: Multifactorial.

Cause: The disease-causing factors are unknown. HLA-B\*51 is strongly associated with BD with



approximately 60% of patients being positive, as opposed to about 15% positivity in healthy individuals across different ethnicities. Due to low specificity, HLA-B\*51 positivity is not diagnostic for BD. It may, however, affect clinical phenotypes of BD as it is more common in patients with ocular involvement, and less common in patients with gastrointestinal involvement.

Effective Date: May 3, 2024

Clinical Sensitivity: Approximately 50-80 percent, depending on ethnicity.

Methodology: Polymerase Chain Reaction/Massively Parallel Sequencing/Sequence-Specific Oligonucleotide Probe Hybridization.

Analytical Sensitivity and Specificity: >99 percent.

Limitations: Other genetic and nongenetic factors that influence BD are not evaluated. Other rare, or novel alleles may occur which may lead to false positive or false negative results. In cases where an HLA allele can not be resolved unambiguously, the allele assignment will be reported as the most common, based on allele frequencies from the Common, Intermediate and Well-Documented Alleles Catalogue version 3.0.0 (Hurley CK, et al, 2020).

Alleles tested: HLA-B\*51 alleles.

Disclaimer Information:

This test was developed and its performance characteristics determined by the Histocompatibility and Immunogenetics Laboratory at the University of Utah Health. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Histocompatibility and Immunogenetics Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

Performed at: Histocompatibility and Immunogenetics Laboratory, University of Utah Health, 417 Wakara Way, Suite 3220, Salt Lake City, UT 84108.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Reference Interval:		



**NEW TEST** 

**Click for Pricing** 

QuantiFERON TB-Gold Plus, 1-Tube

3017554, QFT PLUS

3017554, QFT PLUS			
Specimen Requirements:			
Patient Preparation:			
Collect:	QuantiFERONGold Plus 1-tube (ARUP Supply #54015) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. For collection and transport instructions, refer to QuantiFERON under Special Handling at https://www.aruplab.com/testing/quantiferon#collection. NOTE: The specimen must be submitted in the ARUP-provided collection tube due to the requirements of the laboratory automation.		
Specimen Preparation:	Transport 6 mL whole blood. (Min: 5 mL).		
Transport Temperature:	Refrigerated. Must be collected and shipped directly to ARUP the same calendar day.		
Unacceptable Conditions:	Clotted specimens.		
Remarks:	Do not collect or ship on holidays or the day before holidays.		
Stability:	Ambient: 3 hours; Refrigerated: 48 hours; Frozen: Unacceptable		
Methodology:	Semi-Quantitative Chemiluminescent Immunoassay (CLIA)/Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)		
Performed:	Sun-Sat		
Reported:	1-4 days		
Note:	If the stability requirements cannot be met, please refer to ARUP test code 3017562, QuantiFERON-TB Gold Plus, 4-Tube.		
CPT Codes:	86480		
New York DOH Approval Status: Interpretive Data:	This test is New York DOH approved.		
Interferon gamma release is measured for specimens from each of the four collection tubes. A			

Effective Date: May 20, 2024

qualitative result (Negative, Positive, or Indeterminate) is based on interpretation of the four



values: NIL, MITOGEN minus NIL (MITOGEN-NIL), TB1 minus NIL (TB1-NIL), and TB2 minus NIL (TB2-NIL). The NIL value represents nonspecific reactivity produced by the patient specimen. The MITOGEN-NIL value serves as the positive control for the patient specimen, demonstrating successful lymphocyte activity. The TB1-NIL tube specifically detects CD4+ lymphocyte reactivity, specifically stimulated by the TB1 antigens. The TB2-NIL tube detects both CD4+ and CD8+ lymphocyte reactivity, stimulated by TB2 antigens. An overall Negative result does not completely rule out TB infection.

Effective Date: May 20, 2024

A false-positive result in the absence of other clinical evidence of TB infection is not uncommon. Refer to: Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection -- United States, 2010 (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm), for more information concerning test performance in low-prevalence populations and use in occupational screening.

### Reference Interval:

Test Number	Components	Reference Interval
	QuantiFERON-Mitogen minus NIL	
		No Reference Interval
	QuantiFERON NIL	
		No Reference Interval
	Quantiferon-Plus TB1 minus NIL	
		0.34 IU/mL or less
	Quantiferon-Plus TB2 minus NIL	
		0.34 IU/mL or less



**NEW TEST** 

**Click for Pricing** 

QuantiFERON TB-Gold Plus, 4-Tube

3017562, QFT 4

Specimen Requirements:

Patient Preparation:

Collect: QuantiFERON-TB Gold Plus (Standard) 4-Tube Collection Kit

(ARUP Supply #54012) or QuantiFERON-TB Gold Plus (HIGH ALTITUDE) 4-Tube Collection Kit (ARUP Supply #54010) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. Specimens may remain ambient for up to 16 hours after collection before being placed in an incubator. For collection and transport instructions refer to QuantiFERON under Special Handling at https://www.aruplab.com/testing/quantiferon#collection.

Effective Date: May 20, 2024

Specimen Preparation: Transport plasma in the original containers. (Min: 0.8 mL per

container)

Transport Temperature: Refrigerated

Unacceptable Conditions: Whole blood

Remarks:

Stability: Ambient: 2 hours; Refrigerated: 1 month; Frozen: Unacceptable

Methodology: Semi-Quantitative Chemiluminescent Immunoassay

(CLIA)/Semi-Quantitative Enzyme-Linked Immunosorbent

Assay (ELISA)

Performed: Sun-Sat

Reported: 1-4 days

Note:

CPT Codes: 86480

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Interferon gamma release is measured for specimens from each of the four collection tubes. A qualitative result (Negative, Positive, or Indeterminate) is based on interpretation of the four values: NIL, MITOGEN minus NIL (MITOGEN-NIL), TB1 minus NIL (TB1-NIL), and TB2 minus NIL (TB2-NIL). The NIL value represents nonspecific reactivity produced by the patient specimen. The



MITOGEN-NIL value serves as the positive control for the patient specimen, demonstrating successful lymphocyte activity. The TB1-NIL tube specifically detects CD4+ lymphocyte reactivity, specifically stimulated by the TB1 antigens. The TB2-NIL tube detects both CD4+ and CD8+ lymphocyte reactivity, stimulated by TB2 antigens. An overall Negative result does not completely rule out TB infection.

Effective Date: May 20, 2024

A false-positive result in the absence of other clinical evidence of TB infection is not uncommon. Refer to: Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection -- United States, 2010 (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm), for more information concerning test performance in low-prevalence populations and use in occupational screening.

### Reference Interval:

Test Number	Components	Reference Interval
	QuantiFERON-Mitogen minus NIL	
		No Reference Interval
	QuantiFERON NIL	
		No Reference Interval
	Quantiferon-Plus TB1 minus NIL	
		0.34 IU/mL or less
	Quantiferon-Plus TB2 minus NIL	
		0.34 IU/mL or less



**Click for Pricing** 

Allergen, Food, Wheat Component rTri a 19 Omega 5-Gliadin, IgE

3017565, TRI A 19

Specimen Requirements:

Patient Preparation: Multiple patient encounters should be avoided.

Collect: Serum separator tube.

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection.

Transfer 0.5 mL serum to an ARUP standard transport tube. (Min: 0.25 mL). For multiple allergen orders refer to "Allergen

Effective Date: May 20, 2024

Specimen Collection Instructions" at

www.aruplab.com/testing/resources/specimen.

Transport Temperature: Refrigerated.

Unacceptable Conditions: Hemolyzed, icteric, or lipemic specimens.

Remarks:

Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2

weeks; Frozen: 1 month

Methodology: Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay

Performed: Sun-Sat

Reported: 1-3 days

Note:

CPT Codes: 86008

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:



Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

Effective Date: May 20, 2024

Reporting Range (reported in kU/L)	Probability of IgE Mediated Clinical Reaction	Class Scoring
Less than 0.10	No significant level detected	0
0.10-0.34	Clinical relevance undetermined	0/1
0.35-0.70	Low	1
0.71-3.50	Moderate	2
3.51-17.50	High	3
17.51-50.00	Very high	4
20.01-100.00	Very high	5
Greater than 100.00	Very high	6

### Reference Interval:

Test Number	<b> </b>	Reference Interval
	Wheat rTri a 19	Less than or equal to 0.09 kU/L



## **Click for Pricing**

Allergen, Food, Wheat and nGliadin With Reflex to Components, IgE 3017569, WHEAT R

0011003, 1111211111	
Specimen Requirements:	
Patient Preparation:	Multiple patient encounters should be avoided.
Collect:	Serum separator tube.
Specimen Preparation:	Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP standard transport tube. (Min: 0.35 mL). For multiple allergen orders refer to "Allergen Specimen Collection Instructions" at www.aruplab.com/testing/resources/specimen.
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Hemolyzed, icteric, or lipemic specimens.
Remarks:	
Stability:	After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month
Methodology:	Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
Performed:	Sun-Sat
Reported:	1-3 days
Note:	This assay will initially test wheat whole allergen and purified gliadin. If the wheat whole allergen result is greater than or equal to 0.1 kU/L, wheat component Tri a 14 will be ordered. If the purified gliadin is greater than or equal to 0.1 kU/L, wheat component Tri a 19 will be ordered. Additional charges apply.
CPT Codes:	86003; 86008 if reflexed add 86008 x2
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	

Effective Date: May 20, 2024



Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

Effective Date: May 20, 2024

Reporting Range (reported in kU/L)	Probability of IgE Mediated Clinical Reaction	Class Scoring
Less than 0.10	No significant level detected	0
0.10-0.34	Clinical relevance undetermined	0/1
0.35-0.70	Low	1
0.71-3.50	Moderate	2
3.51-17.50	High	3
17.51-50.00	Very high	4
50.01-100.00	Very high	5
Greater than 100.00	Very high	6

### Reference Interval:

Test Number	Components	Reference Interval
	Allergen, Food, Wheat IgE	Less than or equal to 0.34 kU/L
	Wheat nGliadin	Less than or equal to 0.09 kU/L



**NEW TEST** 

**Click for Pricing** 

RBC Antibody ID Package (IRL)

3017610, IRL AB PKG

Specimen Requirements:

**Patient Preparation:** 

Collect: Lavender (K2EDTA) or pink (K2EDTA) AND plain red.

Specimen Preparation: Do not freeze. Transport 10 mL whole blood (plain red) AND 20

mL whole blood (EDTA). (Min: 7 mL plain red AND 10 mL EDTA).

Effective Date: May 20, 2024

Transport Temperature: Refrigerated. Deliver to lab immediately.

Unacceptable Conditions: Separator tubes.

Remarks:

Stability: Ambient: Unacceptable; Refrigerated: 1 week; Frozen:

Unacceptable

Methodology: Qualitative Hemagglutination (HA)

Performed: Mon-Fri

Reported: 3-5 days

Note: Includes: ABO/Rh type, direct Coombs, RBC antibody

identification, by various methods. Red blood cell antigen testing will be added as indicated. Depending on antibody complexity, additional testing may be required. Additional charges apply. Client must provide patient transfusion history.

CPT Codes: 86900; 86901; 86880; 86870 x3; additional CPT codes may

apply

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

By report



**NEW TEST** 

**Click for Pricing** 

RBC Antibody ID Prenatal - Reflex to Titer

3017611, IRL ABID

Specimen Requirements:

**Patient Preparation:** 

Collect: 3 (7mL) lavender (K2EDTA) or pink (K2EDTA) AND 1 (7mL) plain

red.

Specimen Preparation: Do not freeze. Transport 3 (7 mL) whole blood EDTA AND 1 (7

mL) whole blood plain red. (Min: 10 mL EDTA and 3 mL plain

Effective Date: May 20, 2024

red)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Separator tubes.

Remarks:

Stability: Ambient: Unacceptable; Refrigerated: 1 week; Frozen:

Unacceptable

Methodology: Qualitative Hemagglutination (HA)/Qualitative Solid Phase Red

Cell Adherence

Performed: Mon-Fri

Reported: 3-5 days

Note: This test is for prenatal patients only. Includes: ABO/Rh type,

direct Coombs, RBC antibody identification by one method. Titers will be performed, at an additional charge, on prenatal specimens for clinically significant antibodies. Red blood cell antigen testing will be added as indicated. Depending on antibody complexity, additional testing may be required.

Additional charges apply.

CPT Codes: 86900; 86901; 86880; 86870; additional CPT codes may apply

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Reference Interval:



Test Components Reference Interval

Effective Date: May 20, 2024



**NEW TEST** 

**Click for Pricing** 

PD-L1 22C3 by IHC

3017615, PDL1 22C3

Specimen Requirements:

**Patient Preparation:** 

Collect: Tumor tissue

Specimen Preparation: Formalin fixed (10% neutral buffered formalin) and paraffin

embedded (FFPE) specimen. Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit (ARUP supply #47808 required), available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. (Min: 3 slides)

Effective Date: May 20, 2024

If sending precut slides, do not oven bake.

Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in

cooled container during summer months.

Unacceptable Conditions: Paraffin block with no tumor tissue remaining; specimens fixed

in any fixative other than 10% neutral buffered formalin.

Decalcified specimens. Specimens with fewer than 100 viable

tumor cells.

Remarks: Include surgical pathology report and indicate tissue site with

the test order. For additional technical details, please contact ARUP Client Services at 800-522-2787. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the

ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to

orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification

is provided.

Stability: Paraffin block: Ambient indefinitely, Refrigerated indefinitely,

Frozen: Unacceptable Precut NSCLC slides: Ambient 6 months, Refrigerated 6 months, Frozen: Unacceptable Precut gastric/GEJ adenocarcinoma slides: Ambient: 5 months, Refrigerated 5 months, Frozen: Unacceptable Precut ESCC slides: Ambient 1 month, Refrigerated 4.5 months, Frozen: Unacceptable Precut cervical cancer slides: Ambient 1 month,



Refrigerated 5 months, Frozen: Unacceptable Precut HNSCC slides: Ambient 4 months, Refrigerated 6 months, Frozen: Unacceptable Precut TNBC slides: Ambient 4 months, Refrigerated 7.5 months, Frozen: Unacceptable

Effective Date: May 20, 2024

Methodology: Immunohistochemistry (IHC) Performed: Mon-Fri Reported: 3-7 days Note: This test code includes pathologist interpretation. At least 100 viable tumor cells are required for interpretation. Submission of slides that have been oven baked, or specimens that are decalcified and/or fixed in any fixative other than 10% neutral buffered formalin are not validated and should be interpreted with caution. **CPT Codes:** 88360 New York DOH Approval Status: Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible. Interpretive Data: Refer to report. Reference Interval:



**Click for Pricing** 

Vitamin C, Plasma (High-Dose Therapy)

3017651, VIT C IV

· · · · · · · · · · · · · · · · · ·	
Specimen Requirements:	
Patient Preparation:	
Collect:	Green (sodium or lithium heparin). Place specimen in ice bath immediately. Also acceptable: Plasma separator tube.
Specimen Preparation:	Protect from light, centrifuge, transfer plasma, and freeze within 1 hour of collection. Transfer 0.5 mL plasma to an ARUP amber transport tube. (Min: 0.3 mL)
Transport Temperature:	CRITICAL FROZEN AND LIGHT PROTECTED. Separate specimens must be submitted when multiple tests are ordered.
Unacceptable Conditions:	EDTA plasma, whole blood, or body fluids. Grossly hemolyzed specimens.
Remarks:	Thawing and refreezing of the specimen and exposure to light will result in decreased vitamin C concentration.
Stability:	After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month
Methodology:	Quantitative High Performance Liquid Chromatography- Tandem Mass Spectrometry
Performed:	Sun-Sat
Reported:	1-6 days
Note:	Thawing and refreezing of the specimen and exposure to light will result in decreased vitamin C concentration.
CPT Codes:	82180
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	

Effective Date: May 3, 2024

Intravenous vitamin C (IVC) administration produces millimolar plasma ascorbate (vitamin C) concentrations. Therapeutic concentrations average 15 mmol/L and range from 1-30 mmol/L. The maximum plasma concentration achieved by oral supplementation of vitamin C is approximately 250



Vitamin C concentration is reported as micromoles per liter (). To convert concentration to millimoles per liter (mmol/L), multiply the result by 0.001.

### Reference Interval:

Test Number	Components	Reference Interval
	Vitamin C, Plasma	23-114 u mol/L

Effective Date: May 3, 2024



**NEW TEST** 

**Click for Pricing** 

Alzheimer's Disease Markers, CSF

3017653, ADMRKS CSF

Specimen Requirements:

**Patient Preparation:** 

Collect: CSF

Specimen Preparation: Tube type: Preferred: 2.5 ml low-bind false bottom CSF tube

(Sarstedt, 63.614.625) Acceptable: Sarstedt 72.703.600 (1.5 ml) or Sarstedt 72.694.600 (2 ml) Unacceptable: Polystyrene collection tubes are not acceptable as exposing of CSF to polystyrene tubes may decrease Abeta42 concentrations Collection instructions: 1. Perform lumbar puncture and discard the first 1 to 2 ml of CSF 2. Collect CSF directly into low-bind false bottom CSF tube using the drip method. Avoid use of syringes or extension tubing. Fill tube at least 50% full. 3. Send specimen in original collection tube (do not aliquot) using transport kit (ARUP Supply #55810) available online through eSupply using ARUP Connect (TM) or contract ARUP

Effective Date: May 20, 2024

Client Services at 800-522-2787.

Transport Temperature: -20- Critical frozen

Unacceptable Conditions: Specimen types other than those listed and hemolyzed CSF.

Specimens too viscous to be aspirated by instrument.

Remarks:

Stability: Frozen: 8 weeks

Methodology: Quantitative Electrochemiluminescent Immunoassay (ECLIA)

Performed: Mon

Reported: 1-7 days

Note:

CPT Codes: 83520 x3

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:



Interpretive information: The Alzheimer's Disease Markers, CSF panel is intended for use in adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. The pTau181/Abeta42 and tTau/Abeta42 ratios provide better concordance with amyloid positron emission tomography (PET) imaging when compared to Abeta42, pTau181, and tTau individually.

Effective Date: May 20, 2024

Limitations: Failure to adhere to the sample collection instructions provided in the Lab Test Catalog may result in falsely reduced Abeta42 concentrations and therefore false elevations in the reported ratios. The ratios reported have not been established for predicting development of dementia or other neurologic conditions or for monitoring responses to therapies. Results of this test must always be interpreted in the context other clinical diagnostic evaluations and should not be used alone to establish a diagnosis of AD or other cognitive disorder.

Methodology: Roche Diagnostics Inc. electrochemiluminescence assay was used. Results obtained with different assay methods or kits may be different and cannot be used interchangeably.

with different a	assay memous o	or kits may be different and cannot be used if
Phospho-Tau (181P) CSF/ß- Amyloid (1-42) CSF ratio	Interpretation	
<= 0.023	A negative result, defined as pTau181/Abeta42 ratio value below cutoff, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient's cognitive impairment is due to AD.	
> 0.023	A positive result, defined as pTau181/Abeta42 ratio value above cutoff, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder.	
Total Tau CSF/ß- Amyloid (1-42) CSF ratio	Interpretation	
<= 0.28	A negative result, defined as	



tTau/Abeta42 ratio value below cutoff, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient's cognitive impairment is due to AD. > 0.28 A positive result, defined as tTau/Abeta42 ratio value above cutoff, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder.

Effective Date: May 20, 2024

### Reference Interval:

Test Number	Components	Reference Interval
	Phospho-Tau(181)/Abeta42 Ratio, CSF	<= 0.023
	Total-Tau/Abeta42 Ratio, CSF	<= 0.28



## **Inactivations**

The following will be discontinued from ARUP's test menu on May 20, 2024 Replacement test options are indicated when applicable.

Test Number	Test Name	Refer to Replacement Test
0013003	Antibody ID Package (IRL) (Change effective as of 05/20/24: Refer to 3017610 in the May Hotline)	RBC Antibody ID Package (IRL) (3017610)
0013005	Antibody ID RBC Prenatal-Reflex to Titer (Change effective as of 05/20/24: Refer to 3017610 in the May Hotline)	RBC Antibody ID Prenatal - Reflex to Titer (3017611)
0040248	KRAS Mutation Detection (Inactive as of 05/20/2024)	
0049000	Leukocyte Alkaline Phosphatase (Inactive as of 5/20/2024)	
0051750	BRAF Codon 600 Mutation Detection with Reflex to MLH1 Promoter Methylation (Change effective as of 05/20/24: Refer to 3017204)	BRAF Mutation Detection with Reflex to MLH1 Promoter Methylation (3017204)
0092099	B-Cell CD20 Expression (Change effective as of 03/20/24: Refer to 3016431)	B-Cell CD20 Expression by Flow Cytometry, Quantitative (3016431)
2002440	EGFR Mutation Detection by Pyrosequencing (Inactive as of 05/20/2024)	
2002498	BRAF Codon 600 Mutation Detection by Pyrosequencing (Change effectrive as of 05/20/24: Refer to 3017203)	BRAF Mutation Detection (3017203)
2003036	Aquaporin-4 Receptor Antibody (Change effective as of 05/20/24: Refer to 2013320)	Aquaporin-4 (AQP4) Antibody, IgG by CBA- IFA With Reflex to Titer, Serum (2013320)
2003123	NRAS Mutation Detection by Pyrosequencing (Inactive as of 05/20/2024)	



Test Number	Test Name	Refer to Replacement Test
2005685	Japanese Encephalitis Virus Antibody, IgM by ELISA (Change effective as of 05/20/24: Refer to 2005689)	Japanese Encephalitis Virus Antibodies, IgG and IgM by ELISA (2005689)
2005687	Japanese Encephalitis Virus Antibody, IgG by ELISA (Change effective as of 05/20/24: Refer to 2005689)	Japanese Encephalitis Virus Antibodies, IgG and IgM by ELISA (2005689)
2006444	IDH1 and IDH2 Mutation Analysis, exon 4 (Inactive as of 5/20/2024)	
2011476	Porphobilinogen (PBG), Random Urine(Change effective as of 05/20/24: Refer to 0080260 in the May Hotline)	Porphobilinogen (PBG), Urine(0080260)
2013284	PD-L1 22C3 IHC with Tumor Proportion Score (TPS) Interpretation, pembrolizumab (KEYTRUDA) and cemiplimab-rwlc (LIBTAYO) (Change effective as of 05/20/24: Refer to 3017615)	PD-L1 22C3 IHC (3017615)
2013327	Aquaporin-4 Receptor Antibody by ELISA with Reflex to Aquaporin-4 Receptor Antibody, IgG by IFA (Change effective as of 05/20/24: Refer to 2013320)	Aquaporin-4 (AQP4) Antibody, IgG by CBA- IFA With Reflex to Titer, Serum (2013320)
3000197	PD-L1 22C3 IHC with Combined Positive Score (CPS) Interpretation, pembrolizumab (KEYTRUDA) (Change effective as of 05/20/24: Refer to 3017615)	PD-L1 22C3 IHC (3017615)
3000399	QuantiFERON-TB Gold Plus, 4-Tube (Change effective as of 05/20/24: Refer to 3017562)	QuantiFERON TB-Gold Plus, 4-Tube (3017562)
3000400	QuantiFERON-TB Gold Plus, 1-Tube (Change effective as of 05/20/24: Refer to 3017554)	QuantiFERON-TB Gold Plus, 1-Tube (3017554)



Test Number	Test Name	Refer to Replacement Test
3004267	IDH1 and IDH2 Mutation Analysis Exon 4, Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue (Change effectrive as of 05/20/24: Refer to 3017222)	IDH1 and IDH2 Mutation Detection (3017222)
3006049	Autoimmune Encephalitis Reflex Panel, CSF (Change effective as of 05/20/24: Refer to 3006202, 3006211)	Autoimmune Encephalopathy/Dementia Panel, CSF (3006202), Autoimmune Pediatric CNS Disorders, CSF (3006211)
3006050	Autoimmune Encephalitis Extended Panel, Serum (Change effective as of 05/20/24: Refer to 3006201, 3006210)	Autoimmune Encephalopathy/Dementia Panel, Serum (3006201), Autoimmune Pediatric CNS Disorders, Serum (3006210)
3006285	Adiponectin Quantitative, Serum/Plasma (Available May 3, 2024)	Adiponectin, Quantitative Serum/Plasma (3017195)
3016444	Phospho-Tau/Total-Tau/A Beta42, CSF (Change effective as of 05/20/24: Refer to 3017653 in the May Hotline)	